CD44 targeted functionalized nanocarriers for non-small cell lung cancer

Area of Science:

• Oncology
• Nanotechnology
• Biomaterials

Background:

• Non-small cell lung cancer (NSCLC) presents a global health challenge necessitating innovative treatments.
• CD44, a cell surface glycoprotein, is significantly overexpressed in NSCLC, identifying it as a key therapeutic target.
• Understanding NSCLC molecular characteristics is crucial for developing targeted drug delivery systems.

Purpose of the Study:

• To review the potential of CD44-targeted functionalized nanocarriers for NSCLC treatment.
• To explore CD44 as a biomarker and its role in targeted drug delivery strategies.
• To guide researchers and clinicians in utilizing nanocarrier-based therapies for NSCLC.

Main Methods:

• Review of preclinical and clinical studies on CD44-targeted nanocarriers in NSCLC.
• Analysis of nanocarrier properties (size, morphology, charge) influencing CD44 receptor interaction.
• Assessment of safety considerations, including immunogenicity and off-target effects.

Main Results:

• CD44-targeted nanocarriers demonstrate potential for effective NSCLC treatment.
• Nanocarrier characteristics significantly impact their interaction with CD44 receptors.
• Preclinical and clinical data support the efficacy of this targeted approach.

Conclusions:

• CD44-targeted nanocarriers offer a promising strategy for precise and efficient NSCLC therapy.
• Careful consideration of nanocarrier design and potential safety issues is essential.
• This targeted approach holds potential for advancing NSCLC treatment paradigms.